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This study aims to explore whether the water exchange rate constants in tumor cells can
act as a hallmark of pathology status and a reporter of therapeutic outcomes. It has been
shown, using 4T1 cell cultures and murine allografts, that an early assessment of the
therapeutic effect of doxorubicin can be detected through changes in the cellular water
efflux rate constant kio. The latter has been estimated by analyzing the magnetization
recovery curve in standard NMR T1 measurements when there is a marked difference in
the proton relaxation rate constants (R1) between the intra- and the extra-cellular
compartments. In cellular studies, T1 measurements were carried out on a relaxometer
working at 0.5 T, and the required difference in R1 between the two compartments was
achieved via the addition of a paramagnetic agent into the extracellular compartment. For
in-vivo experiments, the large difference in the R1 values of the two-compartments was
achieved when the T1 measurements were carried out at low magnetic field strengths.
This task was accomplished using a Fast Field Cycling (FFC) relaxometer that was
properly modified to host a mouse in its probe head. The decrease in kio upon the
administration of doxorubicin is the result of the decreased activity of Na+/K+-ATPase, as
shown in an independent test on the cellular uptake of Rb ions. The results reported herein
suggest that kio can be considered a non-invasive, early and predictive biomarker for the
identification of responsive patients immediately from the first doxorubicin treatment.
Keywords: NMR relaxometry, theranostics, doxorubicin, magnetic resonance imaging, cellular water efflux
rate constantINTRODUCTION
Diagnostic imaging tools play a key role in the characterization of complex, heterogeneous and
multifactorial diseases such as cancer. They are often crucial for the selection of the most suitable
therapy and for the evaluation of its outcome, i.e. to increase the chance of success and reduce the
side effects (1). The currently available pharmacological options in the field of breast cancer, whichDecember 2021 | Volume 11 | Article 7788231
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to find means to obtain an early evaluation as to their efficacy.
The World Health Organization (WHO) criteria and Response
Evaluation Criteria in Solid Tumors (RECIST) are based on the
assessment of tumor size in morphological images by Computer
Tomography (CT) and Magnetic Resonance Imaging (MRI) (2,
3). However, volume changes are quite late events and their use
in the evaluation of the undertaken therapy may be an issue
when dealing with a disease for which time is a very important
parameter. Therefore, there is a continuous search for methods
that can report the early effects of therapy, in particular those that
use biomarkers to report changes in tumor metabolic activity.
Currently, metabolic assessments that are based on the use of
positron emission tomography (PET) tracers are widely used as
they reflect the viability of cancer cells and other functional
changes in the response to anticancer treatments (4, 5).
Moreover, the availability of advanced functional magnetic
resonance imaging (fMRI) techniques has furnished new
possibilities in the monitoring of therapeutic responses (6).
There is a growing consensus that MRI protocols may provide
powerful diagnostic tools in the field of oncology (7). Their
diagnostic power arises primarily from disease-induced changes
in the nuclear magnetic resonance (NMR) relaxation times of
tissue, especially in the spin-lattice relaxation time T1 (8, 9).
However, these changes cannot be fully exploited at the magnetic
field strengths of currently available MRI scanners, as changes in
tissue T1 do not appear to be sensitive enough at these field
strengths to report on the response of the tumor cells to therapy.
On the other hand, our group has recently demonstrated that
measuring T1 at lower magnetic field strengths can be very
informative and report on the tumor metabolic status (10, 11).
This is possible because tissue T1 varies with applied magnetic
field strength, with the differences between tissues being higher at
lower magnetic field strengths (12–15). This behavior (often
referred to as “T1-dispersion”, or simply relaxometry) is a marker
of disease, but is invisible to conventional, fixed-field MRI
scanners. Fast Field-Cycling (FFC)-NMR is the only
practicable technique for measuring T1-dispersion. It involves
switching the magnetic field between different field strengths
(from 0.2 to 200 mT, typically) during the measurement
procedure (16). The proton relaxation rate constants (R1 = 1/
T1) of tissues are dependent on the extra/intracellular water ratio
and the water exchange rate between the two compartments (10).
Both terms are affected by tumor-cell metabolism. The relative
amount of water in the two compartments and their exchange
across cellular membranes are significantly different in healthy
and tumor tissues. Recent studies have shown that the osmosis-
and metabolism-driven movement of free water molecules across
membranes, which affect cell volume and shape, may be an
intrinsic and extremely sensitive reporter of pathology and its
energetic deregulation (17–20).
In our previous work (10, 11), we demonstrated that
observing R1 at low magnetic fields can clearly discriminate
between healthy and tumor tissues as well as between different
types of adenocarcinoma breast cancer. The differences in the
observed relaxometric behavior can be accounted for in terms ofFrontiers in Oncology | www.frontiersin.org 2the cellular water efflux rate constant, kio, that can be obtained
from fitting the Magnetization decay acquired on the FFC-NMR
relaxometer. This observation reports on the particular
characteristics of the given tumor cell type. A smaller kio
indicates a s lower water exchange rate across the
transcytolemmal membrane, and this has been shown to be
related to the overexpression/upregulation of the GLUT1 and
Na+/K+-ATPase transporters.
On this basis, FFC-NMR is expected to provide relevant
information about the metabolic mechanisms involved in
disease progression and response to treatment. We hypothesize
that kio may be used as an early predictive biomarker of response
to treatment. In this study, we have performed in-vitro and in-
vivo experiments to evaluate how changes in kio are related to
treatment with doxorubicin, an anthracyline drug, that is
routinely used in the treatment of several cancers including
breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and
Hodgkin’s lymphoma, multiple myeloma, sarcoma and
pediatric cancers (21).MATERIAL AND METHODS
Cell Cultures
The 4T1 (ATCC® CRL-2539™) cell line, initially derived from
spontaneous breast tumor growth in a BALB/c, was purchased
from American Type Culture Collection (ATCC, USA). 4T1-R
was derived from 4T1 (ATCC® CRL-2539™). They were grown
in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS), 100 U/mL Penicillin with 100 mg/ml Streptomycin,
and 4 mM glutamine. Cells were cultured in 5% CO2/95% air at
37°C in a humidified chamber and were split every 2 to 3 days.
All cells tested negative for mycoplasma using the MycoAlert™
Mycoplasma Detection Kit. All materials were purchased from
Lonza (Basel, Switzerland).
Drug-Resistant Cell Line (4T1-R)
4T1-R was derived from 4T1 (ATCC® CRL-2539™), which was
treated for six months with an increased concentration of
doxorubicin (Sigma Aldrich) (from 50 nM to 5 mM) (22–24).
At the confluence of 80%, the cells were seeded for the next
treatment cycle with a higher concentration of the drug. The
acquisition of drug resistance was evaluated using an MTT assay,
based on the reduction of tetrazolium salts to formazan by
mitochondrial succinate dehydrogenase, and quantified
spectrophotometrically. The cells were seeded in 96 multi-well
plates at a density of 10000 cells/well. After 24 h, doxorubicin
(Sigma Aldrich) (1 to 50 mM)) was added to the cell suspensions,
which were then incubated for a further 24 h at 37°C and 5%
CO2. The medium was then removed and 100 ml of Thiazolyl
Blue Tetrazolium Bromide (Sigma Aldrich) was added at a
concentration of 0.45 mg/ml into each well and the plate was
incubated for 4 h at 37°C and 5% CO2. After the removal of the
suspension medium, 150 ml of dimethyl sulfoxide (DMSO) was
added to each well to solubilize the formazan salt crystals thatDecember 2021 | Volume 11 | Article 778823
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minutes, the absorbance was read at 570 nm using an iMark
microplate reader (Biorad). Cell vitality was reported as the
percentage of dead cells relative to the control. The experiment
was performed in quadruplicate and the data were graphically
presented as mean ± SD.
Western Blot
Frozen cells, that had not previously been treated with trypsin for
detachment, were incubated in RIPA lysis buffer (150 mM NaCl;
50 mM Tris-HCl, pH 8.0; sodium dodecyl sulphate (SDS) 0,1%;
sodium deoxycholate 0,5%; Nonidet P-40 1%) supplemented
with 1 mM PMSF, 1 mM NaVO4, 1 mM NaF and protease-
inhibitor cocktail (Sigma-Aldrich) for 40 min on ice. Cell lysates
were centrifuged for 10 min at 14.000 g and the supernatant was
harvested for quantification. The total protein concentration was
quantified using the Pierce™ BCA Protein Assay Kit (Thermo-
Fisher Scientific). After 30 min incubation at room temperature
(when not otherwise specified) in b-mercaptoethanol-containing
Laemmli Sample Buffer (Bio-Rad), equal amounts of protein
lysates (ranging between 30 and 70 mg) were separated via
electrophoresis in a 4-15% Mini-Protean TGX precast gel (Bio-
Rad) and then transferred onto an Immobilion-P PVDF
membrane (0.45 mm pore size, Merck Millipore). After
blocking with either 5% non-fat dry milk (Santa Cruz
Biotechnology) or 5% BSA (Sigma-Aldrich) in wash buffer
(Tris Buffered Saline supplemented with 0.1% Tween-20 - T-
TBS - from Sigma-Aldrich), the membranes were incubated
overnight at 4°C with either rabbit anti-MDR1 (Cat#sc-9313,
clone H-241 Santa Cruz Biotechnology, 1:250 in PBS, 1% BSA)
or mouse anti-b-actin (Cat#sc-69879, Clone AC-15, Santa Cruz
Biotechnology, 1:200 in T-TBS, 5% Milk) antibodies in blocking
buffer. The membranes were then rinsed 3 times in T-TBS and
incubated for 1 hour at room temperature with either HRP-
conjugated anti-rabbit (Cat#A0545, Sigma-Aldrich, 1:2000 in T-
TBS, 5% Milk) or anti-mouse (Cat#A4416, Sigma-Aldrich,
1:2000 in T-TBS, 5% Milk). b-actin was used as the loading
control. The membranes were incubated with Pierce® ECL
Western Blotting Substrate (Thermo-Fisher Scientific) and
images were acquired using a ChemiDoc™ Touch Imaging
System (Bio-Rad).
In-Vitro Determination of Cellular
Membrane Water Exchange Rate
Constants by a Relaxometric Procedure
After Doxorubicin Treatment
The determination of cellular membrane water exchange rate
constants was performed following the protocol described by
Ruggiero et al. (10, 11). 4T1 and 4T1-R were seeded in a 175 cm2
flask at a density of 6 million cells/flask. After 24 h, cells were
incubated with 0, 0.1, 0.5, 1, 5 µM of doxorubicin for a further
24 h (25, 26). The cells were detached using 0.05% trypsin and
0.02% EDTA, washed once with Phosphate Buffer Saline (PBS)
and re-suspended in the presence of 10 mM Gd-HPDO3A
(Prohance, kindly provided by Bracco S.p.A. (Milan, Italy)) in
PBS. The relaxometric measurements were carried out withinFrontiers in Oncology | www.frontiersin.org 315 min, during which cells were transferred to 5 mm NMR tubes
and centrifuged for 5 minutes at 0.1 rcf (4°C). The water proton
T1 values of the cellular pellets were measured at 0.5 T and 25°C
on a Stelar SPINMASTER spectrometer (Stelar, Mede, Italy)
using the inversion-recovery (IR) pulse sequence with 64 t
increments. The apparently biexponential recovery of the
magnetization was observed. The water exchange rate
constants (efflux, kio and influx, koi) across the cell membrane
were determined by analyzing the IR data using the 2SX model
(17, 18).
Determination of Rb Uptake
Seven thousand and fifty cells were plated in 10 cm Ø dishes.
After 24 h, they are incubated with different concentrations of
doxorubicin (from 0 to 5 µM) for a further 24 h. They were then
incubated for 1 h with 0.12 mM RbCl in Earle’s Balanced Salt
Solution (EBSS) at 37°C and 5% CO2. Following four washing
steps with cold PBS to remove the extracellular RbCl, the cells
were harvested. A Bradford assay was used to determine the
protein concentration before acidic digestion. 200 ml of the cell
suspension and 200 ml of HNO3 (70%) were subjected to acidic
mineralization to oxidize the organic matter, solubilize all metals
and simplify the matrix. The microwave (ETHOS UP Milestone,
Bergamo, Italy) heating program consisted of a ramp to 150°C in
6 minutes, followed by 8 min to 150°C. After mineralization,
sample volumes were brought to 3 ml with doubly deionized
water. The quantification of Rb was performed via ICP-MS
(Element-2; Thermo-Finnigan, Rodano (MI), Italy) analysis.
The calibration curve was obtained using absorption standard
solutions (Sigma-Aldrich) in the range 0.2–0.005 mg/mL.
Flow Cytometry
Having performed enzymatic detachment and several washings,
the cells were resuspended in Annexin V binding buffer
(Annexin V Apoptosis Detection Kit APC, eBioscience™) and
incubated in flow cytometry tubes with the Annexin V-APC
reagent, according to manufacturer’s instructions. After 15 min
incubation at room temperature, the cells were rinsed in Annexin
V binding buffer, the tubes were centrifuged and the supernatant
was discarded. DAPI (1 µg/mL; Sigma Aldrich) was added to the
tubes before acquisition with a flow cytometer. The fluorescence
intensity and distribution of the cells were measured using a BD
FACSVerse™ flow cytometer (BD - Becton, Dickinson, and
Company) and the data were analyzed using FlowJo (LLC)
software. Doxorubicin incorporation was estimated based on
the mean fluorescence intensity (MFI) that resulted from
doxorubicin intrinsic fluorescence (lEx 470 nm, lEm 585 nm),
which can be excited with a blue laser (488 nm) and detected
using a PE (586/42 nm) filter. Cells that displayed negative
staining for both Annexin V-APC and DAPI were considered
to be live cells, those that were staining positive for Annexin V-
APC, but negative for DAPI were considered early apoptotic.
Those that were staining double positive were considered late
apoptotic, whereas those staining positive for DAPI only were
considered dead, but not apoptotic. Appropriate negative and
positive controls were used.December 2021 | Volume 11 | Article 778823
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8-week-old female BALB/c mice were inoculated in their hind-
limb muscle with 1 million 4T1 cells suspended in 100 ml of
Phosphate Buffered Saline (PBS). BALB/c mice (Charles River
Laboratories Italia S.r.l., Calco Italia) were maintained under
specific pathogen-free conditions in the animal facility at the
Molecular Biotechnology Center, University of Turin, and
treated in accordance with EU (EU2010/63) and Italian (d.lgs
26/2014) regulations. Before undergoing imaging and nuclear
magnetic resonance experiments, the mice were anesthetized
with a mixture of tiletamine/zolazepam (Zoletil 100; Vibac,
Milan, Italy) 20 mg/kg and xylazine (Rompun; Bayer, Milan,
Italy) 5 mg/kg. The animal treatment protocol was approved by
the Italian Ministry of Health (authorization number 807/2017-
PR). When the tumor reached volumes of around 150-200 mm3,
the animals were treated three times at 1-day intervals (days 0, 2
and 4) intravenously via the tail vein at a dose of 5 mg/kg of
doxorubicin (26–28).
Magnetic Resonance Imaging
T2-weighted images were acquired at 1 T on an Aspect M2-High
Performance MRI System (Aspect Magnet Technologies Ltd.,
Netanya, Israel) consisting of a NdFeB magnet, equipped with a
35 mm solenoid Tx/Tr coil with an inner diameter of 35 mm.
This system is equipped with fast gradient coils (gradient
strength, 450 mT m-1 at 60 A; ramp time, 250 ms at 160 V)
with a field homogeneity of 0.2−0.5 G. MR images were acquired
using a Fast Spin Echo sequence (FSE) (TR 3000 ms; TE 50 ms;
number of slices 11; slice thickness 1 mm; FOV 50x50 mm;
matrix 168 × 160, Flip angle 90°). Tumor volume was determined
using ITK-SNAP software.
In-Vivo Nuclear Magnetic Resonance
Dispersion Profiles (NMRD)
In-vivo NMRD profiles were acquired on the Stelar FFC-NMR
relaxometer (Stelar S.n.c., Mede (PV), Italy), which is equipped
with a 40 mm 0.5 T FC magnet and a dedicated 11 mm solenoid
detection coil. The relaxometer operates under complete
computer control with an absolute uncertainty in the 1/T1
value of ±2%. The typical field sequences used were the Non-
Polarized sequence (NP/S), between 16 and 7 MHz, and the Pre-
Polarized sequence (PP/S), between 7 and 0.01 MHz. The
observation field was set at 14.5 MHz, while the polarization
field was set at 13 MHz. Acquisition was performed using 32 t
over a long-time range (2.8-4 s) in order to sample both the
rapidly and slowly relaxing magnetization components. These
profiles were acquired at seven different relaxation field
strengths (0.01, 0.02, 0.037, 0.07, 0.15, 0.39, 1 MHz in terms
of proton Larmor frequency). During acquisition, murine
temperature was maintained at 25°C using a gel pad. Data
were simultaneously analyzed using Origin software (OriginPro
8.5.0 SR1, OriginLab, Northampton, MA, Levenberg-
Marquardt algorithm, RRID : SCR_014212), in accordance
with the 2SX model (10, 17, 18), sharing the extracellular
volume fraction, Vex, and the extracellular water life time
constant, tex, parameters and maintaining the extracellularFrontiers in Oncology | www.frontiersin.org 4relaxation rate constant, R1ex, fixed to the Matrigel values
obtained in a separated experiment (10). The Vex value was
allowed to vary within a reliable range as reported in the
literature; 0.09-0.19 for healthy mouse hind limbs, and 0.15-
0.5 for tumor mouse hind limbs (18–20, 29, 30).Tunel Assay
Immediately after the NMRD profile was acquired (3 days after
the first doxorubicin treatment), the mice were sacrificed and
perfused, via the vascular system, with a 4% paraformaldehyde
solution as a fixation procedure to obtain the best possible
preservation of the tumor tissue for immunohistochemistry
(31). PFA-fixed and paraffin-embedded Dewaxed 5 mm tumor
sections were stained with the in-situ Apoptosis Detection Kit
(Abcam), according to manufacturer’s protocol.RESULTS AND DISCUSSION
In-Vitro Experiments on Murine
Adenocarcinoma Cells (4T1)
Murine adenocarcinoma 4T1 cells were treated with doxorubicin
(0.1-5 µM) for 24 h. The quantitative determination of the
cellular water efflux rate constant (kio) was carried out by
following a well-established relaxometry-based method at 0.5 T
in the presence of a 10 mM solution of the paramagnetic Gd-
HPDO3A complex in the extracellular space of the cellular
suspension (10, 32–34). The extracellular distribution of the
paramagnetic agent allows a marked difference in proton
relaxation rates to be achieved between the extra- and the
intra-cellular compartments. It follows that the recovery of the
magnetization curve after its selective inversion is characterized
by an apparently bi-exponential behavior, whose fitting yields
estimated values for kio.
In Figure 1A, the obtained kio values are plotted as a function
of the doxorubicin concentrations. The observed variations were
statistically significant at low doses of the drug (0.1 and 0.5 mM)
with P-values of 0.0000499 and 0.000215, respectively. Moreover,
at the same doxorubicin concentrations, the MTT test showed
that the treated cells had high vitality, which is very similar to the
results found in the control experiment (Figure 1B). This finding
is taken as a good indicator to support the view that kio variations
could be considered to be an early predictive biomarker of
treatment response.
We surmise that the observed behavior, induced by the
presence of increasing doses of the drug, can be accounted for
in terms of the cellular system being subjected to a variety of
different effects. In the experiments at low drug concentrations,
the main biologically detectable phenomenon is a decrease in kio,
which is, in principle, associated with an alteration of the
membrane transport system, which is likely due to a decrease
in Na+/K+-ATPase activity, as previously reported (10). In the
case of the experiments at higher concentrations of the drug, one
has to deal with extensive transformations that eventually lead to
cell death. In cancer cells, doxorubicin acts via two principalDecember 2021 | Volume 11 | Article 778823
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topoisomerase-II-mediated DNA repair, with the consequent
generation of free radicals, which damage lipids, DNA and
proteins (21); and, ii) the inhibition of membrane-associated
ion pumps, which is induced by the major metabolite of
doxorubicin, doxorubicinol (21, 35–37). In principle, the two
mechanisms can have opposite effects on kio. The transport
activity of Na+/K+-ATPase was assessed to provide more insight
into the doxorubicin response. The method (38), relies on the
ICP-MS quantification of the cellular uptake of the rubidium ion,
Rb+, which is an established congener for K+ transport by Na+/
K+-ATPase (38, 39). It is well established that this ICP-MS
method provides great accuracy in monitoring metal-ion
transporters in a wide range of cell types and conditions (40).
After doxorubicin treatment, adherent cells were incubated in the
presence of RbCl 0.12 mM for 1 h at 37°C and 5% of CO2. The
uptake of Rb, normalized to the amount of cell proteins,
decreased significantly even in cells treated with the lowest
doses of the drug (i.e. when the concentrations were 0.1 and 0.5Frontiers in Oncology | www.frontiersin.org 5µM, respectively, with a P-value <0.01) (Figure 1C). The decrease
in Rb uptake supports the view that the first effect induced in the
treated cells is a reduced Na+/K+-ATPase efficiency, which, in
turn, is responsible for the observed decrease in water exchange
across the cellular membrane. For 4T1 cells, the amount of Rb per
cell decreased by 30% and 54% upon changing from 0.1 to 5 µM
doxorubicin treatment, respectively.
The response to doxorubicin in terms of cell deaths was
assessed next. Figure 1D reports the percentages of apoptotic
cells as a function of the applied doxorubicin concentrations.
From these results, it is evident that apoptosis occurs only at
higher drug concentrations, which corroborates our working
hypothesis according to which kio variations report early changes
in cellular activity following doxorubicin treatment.
In Vitro Experiments on Doxorubicin-
Resistant 4T1 Cells (4T1-R)
One of the major drawbacks of chemotherapy is drug resistance.
To mimic the acquisition of drug resistance (25), the murineA B
C D
FIGURE 1 | The characterization of 4T1 cells. (A) The cellular water efflux rate constant, kio (s
-1), as determined 24 h after doxorubicin treatment at different drug
concentrations (0.1-5 µM). kio was determined by measuring the water proton relaxation times of cell suspensions in the presence of 10 mM of Gd-HPDO3A at 25°C
on a fixed frequency spectrometer operating at 0.5 T. Data are expressed as the mean ± SD with n ≥7. (B) Percentage of viable cells plotted vs. Log[Doxorubicin]
after 24 h of treatment, obtained using the MTT test. Data are expressed as the mean ± SD of three independent experiments. (C) Cellular uptake of Rb (µmol of
Rb/mg of protein) measured 24 h after doxorubicin treatment. The cells were suspended in a medium containing RbCl 0.12 mM for 1 h at 37°C and 5% of CO2.
Data are expressed as the mean ± SD of three independent experiments. (D) Determination of the % of apoptotic cells after doxorubicin treatment at different
concentrations. The percentage of apoptotic cells was assessed using DAPI-, AnnV-APC+ staining with FACS analysis. Data are expressed as the mean ± SD of
three independent experiments. (***p ≤ 0.001, ****p ≤ 0.0001).December 2021 | Volume 11 | Article 778823
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several cycles with an increased concentration of doxorubicin
(from 50 nM to 1 µM). After six months of treatment, the cells
became resistant to doxorubicin as assessed by the results of the
vitality test (i.e. MTT) (Figure 2B).
In a previous work, the acquisition of drug resistance was
ascribed to the overexpression of ATP binding transporters, such
as the MDR1/P-glycoprotein (Pgp, encoded by the ABCB1 gene)
(25, 41). We can confirm this notion as the western blot analysis
of the MDR1/P-glycoprotein (Figure S1), using both
cytoplasmic and nuclear extracts of 4T1 and 4T1-R cells,
reported the overexpression of this glycoprotein in the resistant
cell line.
The detection of doxorubicin fluorescence is a good reporter
of the intracellular incorporation of the drug. Figure S2 shows
that the fluorescent response was concentration-dependent and
significantly higher in 4T1 than in 4T1-R cells. Further support
was gained by plotting the mean fluorescence intensity (MFI) as
a function of doxorubicin concentration in the incubation
medium. The results confirmed the increased doxorubicinFrontiers in Oncology | www.frontiersin.org 6uptake in wild type 4T1 cells compared to the resistant clone
(Figure S2).
Subsequently, we investigated whether the administration of
doxorubicin has an effect on the transport of water molecules
across the membrane of 4T1-R cells (Figure 2A). The obtained
kio values showed a non-significant decrease and remained
almost constant over the entire range of investigated
doxorubicin concentrations. These results support the view
that the kio decrease in 4T1 cells observed at the low drug
concentrations is due to the specific cytotoxic effect that is
induced by doxorubicin, and not to an aspecific interaction
between doxorubicin and the cell membrane that may
potentially cause a change in cell-membrane permeability,
which, most likely, would also have been present in the 4T1-R
cells. The ICP-MS quantification of Rb confirmed that the
transport activity of Na+/K+-ATPase in 4T1-R was not affected
by the administration of doxorubicin. The uptake of Rb ions,
normalized to the amount of cell proteins, was not significantly
different in the cells treated with different concentrations (0.1
and 5 µM) of the drug, compared to control cells (Figure 2C).A B
C D
FIGURE 2 | The characterization of 4T1-R cells. (A) The cellular water efflux rate constant, kio (s
-1), determined 24 h after doxorubicin treatment at different drug
concentrations (0.1-5 µM). kio values were determined by measuring the water proton relaxation times of cell suspensions in the presence of 10 mM of Gd-HPDO3A
at 25°C on a fixed frequency spectrometer operating at 0.5 T. Data are expressed as the mean ± SD with n= 4. (B) Percentage of viable cells as determined using
the MTT test and plotted vs Log[Doxorubicin] µM. Data are expressed as the mean ± SD of three independent experiments. (C) Cellular uptake of Rb (µmol of Rb/
mg of protein) measured 24 h after doxorubicin treatment. The cells were suspended in a medium containing RbCl 0.12 mM for 1 h at 37°C and 5% of CO2. Data
are expressed as the mean ± SD of three independent experiments. (D) Determination of the % of apoptotic cells after doxorubicin treatment at different
concentrations. The percentage of apoptotic cells was assessed by DAPI-, AnnV-APC+ staining using FACS analysis. Data are expressed as the mean ± SD of three
independent experiments.December 2021 | Volume 11 | Article 778823
Ruggiero et al. Intracellular Water Lifetime as a Tumour BiomarkerThe determination of the percentage of apoptotic cells by FACS
analysis confirmed that the 4T1-R resistant cell line was not
affected by the toxicity of the drug. (Figure 2D).
In-Vivo Experiments: Relaxometric
Assessment of Doxorubicin Treatment in
Balb/c Mice Bearing 4T1 Tumors
To verify the hypothesis that the assessment of kio may be used as
an early predictive biomarker of treatment response in-vivo, an
experimental setup was designed for mammary-tumor-bearing
mice (Figure 3). The determination of kio, via the acquisition of
the FFC-NMR profiles of the tumor region, was carried out
before, during and after drug treatment.
4T1 cells (1x106) were injected into the hind-limb muscle to
obtain the corresponding tumor xenograft for the in-vivo
acquisition of proton relaxation rates at low and variable
magnetic fields. This was carried out using a FFC-relaxometer
that was equipped with a wide bore magnet (40 mm diameter)
that can host a small mouse. The position of the graft
was dictated by the circular shape of the detection coil and its
11 mm diameter (10, 42). Due to the absence of spatial
discrimination, the acquisitions were only carried out on mice
bearing tumors with a volume > 60% of the total leg. Starting
from the sixth day (T6 in the workflow sketch of Figure 3) from
injection, mice (n= 7) were treated with 5 mg/kg of doxorubicin
or with the vehicle (control mice n=7). The treatment was
repeated twice more at three-day intervals. The relaxation
profiles were acquired in the range 0.01-10 MHz three days
after each treatment.
The acquisition of each 1/T1
1H-NMRD profile took about 20
minutes and the temperature of the mice was maintained using a
gel pad heated at 37°C. Figure 4 shows a comparison of the
relaxation profiles acquired in control (untreated tumor) and
doxorubicin-treated mice. Even after the first treatment, a
significant increase in the relaxation rate constants was
observed for the treated mice (P-value at 0.01 MHz = 0.00779).
The larger R1 values observed for the treated mice reflect the
slower water exchange (corresponding to a smaller kio) between
the intra- and extracellular compartments, as seen in the in-vitro
experiments reported above. Here again, treatment withFrontiers in Oncology | www.frontiersin.org 7doxorubicin first resulted in a decrease of kio (due to damage
induced in the transporting system) that, in turn, leads to an
increase in the measured R1 values. The smaller R1 value of the
largest intra-cellular compartment dominates the observed R1 in
the presence of limited exchange between the two compartments.
Interestingly, the effect of doxorubicin treatment was not
detectable in T2-weighted MR images acquired at 1 T, as the
tumor volume was not significantly different in the treated
animals and controls (P > 0.05) (Figure 5A and Figure S3).
This observation indicates that morphological changes need
longer time to be detected thus hampering an early assessment
of the therapeutic outcome.
It follows that, as reported previously (10, 11, 32), the
differences in relaxation rate constants, observed at low
magnetic fields, are related to the occurrence of different water
exchange regimes between the intra and extra-cellular
compartments in the tumor tissue. During the time of an
NMR experiment (or in image acquisition), water molecules
explore both compartments and the observed R1 results from a
mixing of their relaxation rate constants (R1in and R1ex) weighted
by their respective volume fractions (Vin and Vex). Unlike with
high-field measurements, the in-vivo acquisition of a relaxation
dispersion profile between 0.01-1 MHz allows us to work with
differences in the intra- and extra-cellular relaxation rate
constants (R1in and R1ex, respectively) that are large enough to
make the magnetization decay directly dependent on kio (10, 32,
42). As demonstrated both in the cell suspensions and in-vivo
experiments, kio appears to be a good biomarker of tumor-cell
status that can be exploited to non-invasively monitor the early
effects of doxorubicin treatment. Therefore, kio can be measured
in vivo using multi-relaxation rate measurements in the range
0.01-1 MHz and the 2SX model [6,18], without the need to use
paramagnetic contrast agents. Figure 5B shows that a significant
decrease (P=0.000207) in kio was observed 3 days after the first
treatment, providing an early indication of the effect of
doxorubicin on cell metabolism and vitality.
As previously reported and herein confirmed in the Rb-
uptake experiment, one of the important cytotoxic effects of
this antitumor drug is its hampering of Na+/K+-ATPase activity.
After the second and the third treatment, kio returns to the initialFIGURE 3 | Schematic representation of the workflow for the assessment of doxorubicin treatment in 4T1 tumor animal models over a time course of 15 days (T0-T15).December 2021 | Volume 11 | Article 778823
Ruggiero et al. Intracellular Water Lifetime as a Tumour Biomarkervalue. We think that this result reflects the massive death of
tumor cells, which completely permeabilizes the cytosolic
membrane to water. Accordingly, Figure 5C shows an initial
decrease in Vex, as a consequence of the decreased kio, followed
by an increase in Vex after the 2
nd and 3rd treatments. The
observed increase in Vex is, again, a direct consequence of the cell
death caused by doxorubicin. Once the membrane of the dead
cells becomes fully permeable to water, the corresponding
volume occupied by these cells becomes part of the Vex
compartment. These results are in good agreement with the
histological apoptosis evaluation on the slices of tumors, that
were recovered 3 days after the first treatment, using the TUNEL
(terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick‐end labeling) assay. Figure 6 shows that
there are more apoptotic cells in the treated sample than in the
control, suggesting that both kio and Vex may act as biomarkers
for the toxic effect of doxorubicin, significantly earlier than the
macroscopic observation associated to the morphological
changes related to slower tumor growth. Finally, it is
important to notice that in vivo kio magnitude is reduced by a
factor of ~25, (Figure 5B) in respect to the in vitro values
(Figures 1 and 2). There are many possible reasons to account
for the observed behaviour. Cells within a tissue interact with
neighbouring cells and with the extracellular matrix in a very
different fashion in respect to what occurs in cellular pellets. This
may result in significant modification of cell properties, size,
morphology, elasticity, etc., i.e. properties that, in turn, may
affect both passive and energetically driven components of water
exchange across the cellular membrane. One may also expect
that the high interstitial fluid pressure/flow and the low
lymphatic drainage, in particular in the inner core of a solid
tumor (43), may play a role in the translation from in vivo to in
vitro studies. Likely the cells in culture take up more nutrients
than in tissue and this would favour the view that the main
determinant of the observed change relies on the increasedFrontiers in Oncology | www.frontiersin.org 8metabolic activity of the tumour cells. Interestingly, upon
comparing cell lines, characterized by different metabolic
activities, it was found that the differences in kio observed in
vivo in tumour tissues are maintained in vitro (10). Analogously,A
B
C
FIGURE 5 | In-vivo assessment of doxorubicin treatment in Balb/c mice
that bear 4T1 tumors: (A) The percentage of volume increase in the
tumor region as determined by T2-weighted images acquired at 1 T using
the ITK-SNAP software. Open and filled bars correspond to untreated
and treated mice, respectively; (B) The cellular water efflux rate constant,
kio (s
-1) and (C) The extra-cellular volume fractions (Vex) were calculated
via the analysis of the multi-relaxation rate measurements in the range
0.01-1MHz using the 2SX model for treated animals (n=8) compared to
control animals (n=7). Error bars represent the SD of the experimental
data. (***p ≤ 0.001).FIGURE 4 | 1/T1
1H-NMRD profiles of tumor-bearing mouse legs: treated
animals (n=7), black square, compared to control animals (n=7), empty circle.
Error bars represent the SE of the experimental data. (p value at 0.01
MHz = 0.0078).December 2021 | Volume 11 | Article 778823
Ruggiero et al. Intracellular Water Lifetime as a Tumour Biomarkerin this study, it was observed that the effect of doxorubicin
treatment in vivo is maintained in the in vitro experimentCONCLUSION
In summary, the results reported herein show that relaxometric
measurements using FFC-NMR on tumor specimens can
provide an important diagnostic contribution for the early
assessment of the therapeutic effects associated with the
application of doxorubicin. This method is based on the
exploitation of the changes in the MR proton water signal that
are induced by water exchange rate across the cellular
membrane, causing a variation in Vex. It appears to act as a
hallmark that can report on the status of the tumor and its
response to treatment. The herein-reported results suggest that
kio can be considered an early and predictive biomarker for the
identification of responsive patients after the first treatment with
doxorubicin. Even though FFC-NMR instrumentation is not
endowed with spatial resolution, the knowledge obtained in
this study can facilitate new diagnostic opportunities for the
determination of therapeutic outcomes that would be possibleFrontiers in Oncology | www.frontiersin.org 9with FFC MRI scanners. Two prototypes of human whole-body-
sized FFC-MRI scanners have recently been built at Aberdeen
University by Lurie and coworkers (44–46).DATA AVAILABILITY STATEMENT
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